Evaluation of the Midterm Results of the 5C® MEDic Knee System
This prospective study wants to demonstrate the safety and clinical performance of the 5C® MEDic Knee System following total knee arthroplasty. Additionally, all observed product-related complications are documented during the course of the follow-up study. These observations help to re-assess current (known) risks and identify new ones. The data obtained during this study is part of the post market surveillance.
• Voluntary written informed consent of the participant has been obtained prior to any screening procedures
• At least 18 years of age at the time of signing the Informed Consent Form (ICF)
• The patient will be operated at the Leuven University Hospital (primary or revision surgery).
• The patient will receive the 5C® MEDic Knee System (manufactured by implantcast GmbH).
• The implantation will be performed according to the medical indications listed in the product specific Instruction for Use (IFU):
‣ Non-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis,
⁃ Post-traumatic osteoarthritis
⁃ Treatment of fractures that are unmanageable using other surgical techniques
⁃ Rheumatoid arthritis
⁃ Revision arthroplasty (revision prosthesis)
• The patient is willing and able to follow all study specific procedures and to attend the follow-up visits at the study site
• The patient agrees to be contacted by telephone or by mail.